The Felsenstein Medical Research Center
TOPIC

Laboratory of Experimental Hematology

Head of Laboratory: Ofer Shpilberg M.D.

Head of Research Group: : Galit Granot Ph.D.

  Tel: 972-3-9376795
Fax: 972-3-9378201/2, 9376744
E-mail: ofers@clalit.org.il

Research Topics

  1. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.

  2. The effect of retinoic-acid on NB4 cell adhesion and migration through Pyk2 signaling (in collaboration with Prof. Pia Raanani).

  3. Distinctive miRNA expression profiles and functional role in K562 cells and in cells from chronic myeloid leukemia patients.

  4. Sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.

  5. Characterization of aGVHD following allogeneic bone marrow transplantation .

  6. Characterization of donor T-cells at the onset and relapse of acute leukemia.


Selected Publications

  1. Hallak M, Vazana L, Shpilberg O, Levy I, Mazar J, Nathan I. A molecular mechanism for mimosine-induced apoptosis involving oxidative stress and mitochondrial activation. Apoptosis 13(1):147-55, 2008. MEDLINE

  2. Mor-Tzuntz, Uziel O, Shpilberg O, Lahav J, Raanani R, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G. The effect of imatinib mesylate on the signal transduction cascade leading to down regulation of telomerase activity in K562 cells (BCR-ABL positive cells) and in K562 cells resistant to imatinib mesylate Exp Hematol. ;38(1):27-37, 2010. MEDLINE

  3. Hershkovitz Rokah O, Shpilberg O, Granot G. NAD(P)H Quinone oxidoreductase protects TAp63γ from proteasomal degradation and regulates TAp63γ-dependent growth arrest.PLoS One. 30;5(6):e11401, 2010. MEDLINE

  4. Hershkovitz Rokah O, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Shpilberg O. Downregulation of mir-31, mir-155, and mir-564 in chronic myeloid leukemia cells. PLoS One. 7(4):e35501, 2012. MEDLINE

  5. Shapira S, Granot G, Mor-Tzuntz R, Raanani P, Uziel O, Lahav M, Shpilberg O. Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. Cancer Lett. ;323(2):223-31 2012 MEDLINE